BRAF inhibitor

DRUG CLASS:

BRAF inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria Nat Med - 1 week (New C3) trametinib + dabrafenib + PDR001 Sensitive : C2 Nat Med - 1wk	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria Nat Med - 1 week trametinib + dabrafenib + PDR001 Sensitive : C2 Nat Med - 1 week - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks (New C3) cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2wk	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks (New D) vemurafenib Sensitive : C1 J Transl Med - 3wk	vemurafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks vemurafenib Sensitive : C1 J Transl Med - 3 weeks - (New D)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks (New D) dabrafenib Sensitive : C1 J Transl Med - 3wk	dabrafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks dabrafenib Sensitive : C1 J Transl Med - 3 weeks - (New D)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks (New C3) erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 3wk	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	vemurafenib + rituximab Sensitive: A2 - Guideline vemurafenib + rituximab Sensitive : A2	vemurafenib + rituximab Sensitive: A2 - Guideline vemurafenib + rituximab Sensitive : A2
BRAF V600E	Neuroendocrine Tumor	BRAF V600E	Neuroendocrine Tumor	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline dabrafenib + granisetron intravenous Sensitive : A2	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline dabrafenib + granisetron intravenous Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2

BRAF inhibitor

BRAF inhibitor

Associations(621)

Associations
(621)